Top

Published in:

Open Access 20-09-2023 | Heart Failure

Assessment and management of heart failure in patients with chronic kidney disease

Authors: Andrea Igoren Guaricci, Francesca Sturdà, Roberto Russo, Paolo Basile, Andrea Baggiano, Saima Mushtaq, Laura Fusini, Fabio Fazzari, Fulvio Bertandino, Francesco Monitillo, Maria Cristina Carella, Marco Simonini, Gianluca Pontone, Marco Matteo Ciccone, Giuseppe Grandaliano, Giuseppe Vezzoli, Francesco Pesce

Published in: Heart Failure Reviews | Issue 2/2024

Abstract

Heart failure (HF) and chronic kidney disease (CKD) are two pathological conditions with a high prevalence in the general population. When they coexist in the same patient, a strict interplay between them is observed, such that patients affected require a clinical multidisciplinary and personalized management. The diagnosis of HF and CKD relies on signs and symptoms of the patient but several additional tools, such as blood-based biomarkers and imaging techniques, are needed to clarify and discriminate the main characteristics of these diseases. Improved survival due to new recommended drugs in HF has increasingly challenged physicians to manage patients with multiple diseases, especially in case of CKD. However, the safe administration of these drugs in patients with HF and CKD is often challenging. Knowing up to which values of creatinine or renal clearance each drug can be administered is fundamental. With this review we sought to give an insight on this sizable and complex topic, in order to get clearer ideas and a more precise reference about the diagnostic assessment and therapeutic management of HF and CKD.

Bui AL, Horwich TB, Fonarow GC (2011) Epidemiology and risk profile of heart failure. Nat Rev Cardiol 8:30–41. https://doi.org/10.1038/nrcardio.2010.165CrossRefPubMed

Triposkiadis F, Giamouzis G, Parissis J, Starling RC, Boudoulas H, Skoularigis J, Butler J, Filippatos G (2016) Reframing the association and significance of co-morbidities in heart failure. Eur J Heart Fail 18:744–758. https://doi.org/10.1002/ejhf.600CrossRefPubMed

Damman K, Tang WH, Testani JM, McMurray JJ (2014) Terminology and definition of changes renal function in heart failure. Eur Heart J 35:3413–3416. https://doi.org/10.1093/eurheartj/ehu320CrossRefPubMedPubMedCentral

Damman K, Valente MA, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL (2014) Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 35:455–469. https://doi.org/10.1093/eurheartj/eht386CrossRefPubMed

Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, Chambless LE, Coresh J (2007) Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 18:1307–1315. https://doi.org/10.1681/ASN.2006101159CrossRefPubMed

Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J, Committee ASA Investigators (2007) High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 13:422–430. https://doi.org/10.1016/j.cardfail.2007.03.011

Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP, Committee ASA et al (2005) Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149:209–216. https://doi.org/10.1016/j.ahj.2004.08.005CrossRefPubMed

Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH et al (2006) Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113:671–678. https://doi.org/10.1161/CIRCULATIONAHA.105.580506CrossRefPubMed

Damman K, Testani JM (2015) The kidney in heart failure: an update. Eur Heart J 36:1437–1444. https://doi.org/10.1093/eurheartj/ehv010CrossRefPubMedPubMedCentral

10.

Ronco C, Ronco F (2012) Cardio-renal syndromes: a systematic approach for consensus definition and classification. Heart Fail Rev 17:151–160. https://doi.org/10.1007/s10741-010-9224-0CrossRefPubMed

11.

Junho CVC, Trentin-Sonoda M, Panico K, Dos Santos RSN, Abrahao MV, Vernier ICS, Furstenau CR, Carneiro-Ramos MS (2022) Cardiorenal syndrome: long road between kidney and heart. Heart Fail Rev 27:2137–2153. https://doi.org/10.1007/s10741-022-10218-wCrossRefPubMed

12.

Lofman I, Szummer K, Dahlstrom U, Jernberg T, Lund LH (2017) Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. Eur J Heart Fail 19:1606–1614. https://doi.org/10.1002/ejhf.821CrossRefPubMed

13.

Moertl D, Berger R, Struck J, Gleiss A, Hammer A, Morgenthaler NG, Bergmann A, Huelsmann M, Pacher R (2009) Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J Am Coll Cardiol 53:1783–1790. https://doi.org/10.1016/j.jacc.2009.01.057CrossRefPubMed

14.

Guaricci AI, Pontone G, Fusini L, De Luca M, Cafarelli FP, Guglielmo M, Baggiano A, Beltrama V, Muscogiuri G, Mushtaq S et al (2017) Additional value of inflammatory biomarkers and carotid artery disease in prediction of significant coronary artery disease as assessed by coronary computed tomography angiography. Eur Heart J Cardiovasc Imaging 18:1049–1056. https://doi.org/10.1093/ehjci/jew173CrossRefPubMed

15.

Mahmood U, Johnson DW, Fahim MA (2017) Cardiac biomarkers in dialysis. AIMS Genet 4:1–20. https://doi.org/10.3934/genet.2017.1.1

16.

Fahim MA, Hayen A, Horvath AR, Dimeski G, Coburn A, Johnson DW, Hawley CM, Campbell SB, Craig JC (2015) N-terminal pro-B-type natriuretic peptide variability in stable dialysis patients. Clin J Am Soc Nephrol 10:620–629. https://doi.org/10.2215/CJN.09060914CrossRefPubMedPubMedCentral

17.

Horii M, Matsumoto T, Uemura S, Sugawara Y, Takitsume A, Ueda T, Nakagawa H, Nishida T, Soeda T, Okayama S et al (2013) Prognostic value of B-type natriuretic peptide and its amino-terminal proBNP fragment for cardiovascular events with stratification by renal function. J Cardiol 61:410–416. https://doi.org/10.1016/j.jjcc.2013.01.015CrossRefPubMed

18.

Zelenak C, Chavanon ML, Tahirovic E, Trippel TD, Tscholl V, Stroux A, Veskovic J, Apostolovic S, Obradovic D, Zdravkovic M et al (2019) Early NT-proBNP and MR-proANP associated with QoL 1 year after acutely decompensated heart failure: secondary analysis from the MOLITOR trial. Biomark Med 13:1493–1507. https://doi.org/10.2217/bmm-2019-0083CrossRefPubMed

19.

Schaub JA, Coca SG, Moledina DG, Gentry M, Testani JM, Parikh CR (2015) Amino-terminal pro-B-type natriuretic peptide for diagnosis and prognosis in patients with renal dysfunction: a systematic review and meta-analysis. JACC Heart Fail 3:977–989. https://doi.org/10.1016/j.jchf.2015.07.014CrossRefPubMedPubMedCentral

20.

Sato Y (2013) Diagnostic and prognostic property of NT-proBNP in patients with renal dysfunction. J Cardiol 61:446–447. https://doi.org/10.1016/j.jjcc.2013.01.013CrossRefPubMed

21.

Hollenberg SM, Warner Stevenson L, Ahmad T, Amin VJ, Bozkurt B, Butler J, Davis LL, Drazner MH, Kirkpatrick JN, Peterson PN et al (2019) 2019 ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 74:1966–2011. https://doi.org/10.1016/j.jacc.2019.08.001CrossRefPubMed

22.

Glorieux G, Vanholder R, Van Biesen W, Pletinck A, Schepers E, Neirynck N, Speeckaert M, De Bacquer D, Verbeke F (2021) Free p-cresyl sulfate shows the highest association with cardiovascular outcome in chronic kidney disease. Nephrol Dial Transplant 36:998–1005. https://doi.org/10.1093/ndt/gfab004CrossRefPubMed

23.

Sapa H, Gutierrez OM, Shlipak MG, Katz R, Ix JH, Sarnak MJ, Cushman M, Rhee EP, Kimmel PL, Vasan RS et al (2022) Association of uremic solutes with cardiovascular death in diabetic kidney disease. Am J Kidney Dis 80:502–512.e501. https://doi.org/10.1053/j.ajkd.2022.02.016

24.

Sun J, Axelsson J, Machowska A, Heimburger O, Barany P, Lindholm B, Lindstrom K, Stenvinkel P, Qureshi AR (2016) Biomarkers of cardiovascular disease and mortality risk in patients with advanced CKD. Clin J Am Soc Nephrol 11:1163–1172. https://doi.org/10.2215/CJN.10441015CrossRefPubMedPubMedCentral

25.

Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G et al (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139:137–147. https://doi.org/10.7326/0003-4819-139-2-200307150-00013CrossRefPubMed

26.

Khwaja A (2012) KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 120:c179-184. https://doi.org/10.1159/000339789CrossRefPubMed

27.

Kimura K, Morita H, Daimon M, Horio M, Kawata T, Nakao T, Hirokawa M, Kitao R, Watanabe D, Komori T et al (2016) Utility of cystatin C for estimating glomerular filtration rate in patients with muscular dystrophy. Int Heart J 57:386–388. https://doi.org/10.1536/ihj.15-461CrossRefPubMed

28.

Peralta CA, Katz R, Sarnak MJ, Ix J, Fried LF, De Boer I, Palmas W, Siscovick D, Levey AS, Shlipak MG (2011) Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol 22:147–155. https://doi.org/10.1681/ASN.2010050483CrossRefPubMedPubMedCentral

29.

Lassus J, Harjola VP, Sund R, Siirila-Waris K, Melin J, Peuhkurinen K, Pulkki K, Nieminen MS, Group FAS (2007) Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J 28:1841–1847. https://doi.org/10.1093/eurheartj/ehl507

30.

Zivlas C, Triposkiadis F, Psarras S, Giamouzis G, Skoularigis I, Chryssanthopoulos S, Kapelouzou A, Ramcharitar S, Barnes E, Papasteriadis E et al (2017) Left atrial volume index in patients with heart failure and severely impaired left ventricular systolic function: the role of established echocardiographic parameters, circulating cystatin C and galectin-3. Ther Adv Cardiovasc Dis 11:283–295. https://doi.org/10.1177/1753944717727498CrossRefPubMedPubMedCentral

31.

Mortara A, Bonadies M, Mazzetti S, Fracchioni I, Delfino P, Chioffi M, Bersano C, Specchia G (2013) Neutrophil gelatinase-associated lipocalin predicts worsening of renal function in acute heart failure: methodological and clinical issues. J Cardiovasc Med (Hagerstown) 14:629–634. https://doi.org/10.2459/JCM.0b013e3283629ca6CrossRefPubMed

32.

Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw SM, Bell M, Bihorac A, Birkhahn R, Cely CM, Chawla LS et al (2013) Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care 17:R25. https://doi.org/10.1186/cc12503CrossRefPubMedPubMedCentral

33.

Kestenbaum B, Sachs MC, Hoofnagle AN, Siscovick DS, Ix JH, Robinson-Cohen C, Lima JA, Polak JF, Blondon M, Ruzinski J et al (2014) Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis. Circ Heart Fail 7:409–417. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000952CrossRefPubMedPubMedCentral

34.

Lutsey PL, Alonso A, Selvin E, Pankow JS, Michos ED, Agarwal SK, Loehr LR, Eckfeldt JH, Coresh J (2014) Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the Atherosclerosis Risk in Communities study. J Am Heart Assoc 3:e000936. https://doi.org/10.1161/JAHA.114.000936

35.

Bergmark BA, Udell JA, Morrow DA, Cannon CP, Steen DL, Jarolim P, Budaj A, Hamm C, Guo J, Im K et al (2018) Association of fibroblast growth factor 23 with recurrent cardiovascular events in patients after an acute coronary syndrome: a secondary analysis of a randomized clinical trial. JAMA Cardiol 3:473–480. https://doi.org/10.1001/jamacardio.2018.0653CrossRefPubMedPubMedCentral

36.

Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM et al (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121:4393–4408. https://doi.org/10.1172/JCI46122CrossRefPubMedPubMedCentral

37.

Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R et al (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119:2545–2552. https://doi.org/10.1161/CIRCULATIONAHA.108.844506CrossRefPubMedPubMedCentral

38.

Pi M, Ye R, Han X, Armstrong B, Liu X, Chen Y, Sun Y, Quarles LD (2018) Cardiovascular interactions between fibroblast growth factor-23 and angiotensin II. Sci Rep 8:12398. https://doi.org/10.1038/s41598-018-30098-1CrossRefPubMedPubMedCentralADS

39.

Leifheit-Nestler M, Kirchhoff F, Nespor J, Richter B, Soetje B, Klintschar M, Heineke J, Haffner D (2018) Fibroblast growth factor 23 is induced by an activated renin-angiotensin-aldosterone system in cardiac myocytes and promotes the pro-fibrotic crosstalk between cardiac myocytes and fibroblasts. Nephrol Dial Transplant 33:1722–1734. https://doi.org/10.1093/ndt/gfy006CrossRefPubMed

40.

Wohlfahrt P, Melenovsky V, Kotrc M, Benes J, Jabor A, Franekova J, Lemaire S, Kautzner J, Jarolim P (2015) Association of fibroblast growth factor-23 levels and angiotensin-converting enzyme inhibition in chronic systolic heart failure. JACC Heart Fail 3:829–839. https://doi.org/10.1016/j.jchf.2015.05.012CrossRefPubMed

41.

Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, Zhang X, Nessel L, Hamano T, Grunwald JE et al (2014) Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol 25:349–360. https://doi.org/10.1681/ASN.2013050465CrossRefPubMed

42.

Hu MC, Shi M, Gillings N, Flores B, Takahashi M, Kuro OM, Moe OW (2017) Recombinant alpha-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy. Kidney Int 91:1104–1114. https://doi.org/10.1016/j.kint.2016.10.034CrossRefPubMedPubMedCentral

43.

Xie J, Yoon J, An SW, Kuro-o M, Huang CL (2015) Soluble Klotho protects against uremic cardiomyopathy independently of fibroblast growth factor 23 and phosphate. J Am Soc Nephrol 26:1150–1160. https://doi.org/10.1681/ASN.2014040325CrossRefPubMed

44.

Cai J, Zhang L, Chen C, Ge J, Li M, Zhang Y, Liu H, Song B (2023) Association between serum Klotho concentration and heart failure in adults, a cross-sectional study from NHANES 2007–2016. Int J Cardiol 370:236–243. https://doi.org/10.1016/j.ijcard.2022.11.010CrossRefPubMed

45.

Shah S, Henry A, Roselli C, Lin H, Sveinbjornsson G, Fatemifar G, Hedman AK, Wilk JB, Morley MP, Chaffin MD et al (2020) Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nat Commun 11:163. https://doi.org/10.1038/s41467-019-13690-5CrossRefPubMedPubMedCentralADS

46.

Wellcome Trust Case Control C (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447:661–678. https://doi.org/10.1038/nature05911

47.

Shrivastava A, Haase T, Zeller T, Schulte C (2020) Biomarkers for heart failure prognosis: proteins, genetic scores and non-coding RNAs. Front Cardiovasc Med 7:601364. https://doi.org/10.3389/fcvm.2020.601364

48.

Guglielmo M, Baggiano A, Muscogiuri G, Fusini L, Andreini D, Mushtaq S, Conte E, Annoni A, Formenti A, Mancini EM et al (2019) Multimodality imaging of left atrium in patients with atrial fibrillation. J Cardiovasc Comput Tomogr 13:340–346. https://doi.org/10.1016/j.jcct.2019.03.005CrossRefPubMed

49.

Cameli M, Sciaccaluga C, Loiacono F, Simova I, Miglioranza MH, Nistor D, Bandera F, Emdin M, Giannoni A, Ciccone MM et al (2019) The analysis of left atrial function predicts the severity of functional impairment in chronic heart failure: The FLASH multicenter study. Int J Cardiol 286:87–91. https://doi.org/10.1016/j.ijcard.2019.03.063CrossRefPubMed

50.

Gaibazzi N, Porter T, Lorenzoni V, Pontone G, De Santis D, De Rosa A, Guaricci AI (2017) Effect of coronary revascularization on the prognostic value of stress myocardial contrast wall motion and perfusion imaging. J Am Heart Assoc 6. https://doi.org/10.1161/jaha.117.006202

51.

Merlo M, Pagura L, Porcari A, Cameli M, Vergaro G, Musumeci B, Biagini E, Canepa M, Crotti L, Imazio M et al (2022) Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey. Eur J Heart Fail 24:1377–1386. https://doi.org/10.1002/ejhf.2504CrossRefPubMed

52.

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J et al (2022) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 24:4–131. https://doi.org/10.1002/ejhf.2333

53.

Guaricci AI, Chiarello G, Gherbesi E, Fusini L, Soldato N, Siena P, Ursi R, Ruggieri R, Guglielmo M, Muscogiuri G et al (2022) Coronary-specific quantification of myocardial deformation by strain echocardiography may disclose the culprit vessel in patients with non-ST-segment elevation acute coronary syndrome. Eur Heart J Open 2:oeac010. https://doi.org/10.1093/ehjopen/oeac010

54.

Basile P, Guaricci AI, Piazzolla G, Volpe S, Vozza A, Benedetto M, Carella MC, Santoro D, Monitillo F, Baggiano A et al (2023) Improvement of left ventricular global longitudinal strain after 6-month therapy with GLP-1RAs semaglutide and dulaglutide in type 2 diabetes mellitus: a pilot study. J Clin Med 12. https://doi.org/10.3390/jcm12041586

55.

Hassanin N, Alkemary A (2016) Early detection of subclinical uremic cardiomyopathy using two-dimensional speckle tracking echocardiography. Echocardiography 33:527–536. https://doi.org/10.1111/echo.13120CrossRefPubMed

56.

Krishnasamy R, Isbel NM, Hawley CM, Pascoe EM, Leano R, Haluska BA, Stanton T (2014) The association between left ventricular global longitudinal strain, renal impairment and all-cause mortality. Nephrol Dial Transplant 29:1218–1225. https://doi.org/10.1093/ndt/gfu004CrossRefPubMed

57.

Frea S, Pidello S, Bovolo V, Iacovino C, Franco E, Pinneri F, Galluzzo A, Volpe A, Visconti M, Peirone A et al (2016) Prognostic incremental role of right ventricular function in acute decompensation of advanced chronic heart failure. Eur J Heart Fail 18:564–572. https://doi.org/10.1002/ejhf.504CrossRefPubMed

58.

Maeder MT, Holst DP, Kaye DM (2008) Tricuspid regurgitation contributes to renal dysfunction in patients with heart failure. J Card Fail 14:824–830. https://doi.org/10.1016/j.cardfail.2008.07.236CrossRefPubMed

59.

Pellicori P, Carubelli V, Zhang J, Castiello T, Sherwi N, Clark AL, Cleland JG (2013) IVC diameter in patients with chronic heart failure: relationships and prognostic significance. JACC Cardiovasc Imaging 6:16–28. https://doi.org/10.1016/j.jcmg.2012.08.012CrossRefPubMed

60.

Cowie B, Kluger R, Rex S, Missant C (2015) Noninvasive estimation of left atrial pressure with transesophageal echocardiography. Ann Card Anaesth 18:312–316. https://doi.org/10.4103/0971-9784.159799CrossRefPubMedPubMedCentral

61.

Park JH, Marwick TH (2011) Use and Limitations of E/e’ to Assess Left Ventricular Filling Pressure by Echocardiography. J Cardiovasc Ultrasound 19:169–173. https://doi.org/10.4250/jcu.2011.19.4.169CrossRefPubMedPubMedCentral

62.

Faubel S, Patel NU, Lockhart ME, Cadnapaphornchai MA (2014) Renal relevant radiology: use of ultrasonography in patients with AKI. Clin J Am Soc Nephrol 9:382–394. https://doi.org/10.2215/CJN.04840513CrossRefPubMed

63.

Iida N, Seo Y, Sai S, Machino-Ohtsuka T, Yamamoto M, Ishizu T, Kawakami Y, Aonuma K (2016) Clinical implications of intrarenal hemodynamic evaluation by doppler ultrasonography in heart failure. JACC Heart Fail 4:674–682. https://doi.org/10.1016/j.jchf.2016.03.016CrossRefPubMed

64.

Delos Santos RB, Gmurczyk A, Obhrai JS, Watnick SG (2010) Cardiac evaluation prior to kidney transplantation. Semin Dial 23:324–329. https://doi.org/10.1111/j.1525-139X.2010.00725.xCrossRefPubMedPubMedCentral

65.

Chadban SJ, Ahn C, Axelrod DA, Foster BJ, Kasiske BL, Kher V, Kumar D, Oberbauer R, Pascual J, Pilmore HL et al (2020) KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation. Transplantation 104:S11–S103. https://doi.org/10.1097/TP.0000000000003136CrossRefPubMed

66.

(2005) K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 45:S1–153

67.

Chiu DY, Green D, Abidin N, Sinha S, Kalra PA (2015) Cardiac imaging in patients with chronic kidney disease. Nat Rev Nephrol 11:207–220. https://doi.org/10.1038/nrneph.2014.243CrossRefPubMed

68.

Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M, Jabehdar Maralani P, Shabana W, Tang A, Tsampalieros A et al (2018) Gadolinium-based contrast agents in kidney disease: comprehensive review and clinical practice guideline issued by the Canadian Association of Radiologists. Can Assoc Radiol J 69:136–150. https://doi.org/10.1016/j.carj.2017.11.002CrossRefPubMed

69.

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O et al (2022) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Rev Esp Cardiol (Engl Ed) 75:523. https://doi.org/10.1016/j.rec.2022.05.005CrossRefPubMed

70.

Bhandari S, Mehta S, Khwaja A, Cleland JGF, Ives N, Brettell E, Chadburn M, Cockwell P, Investigators SAT (2022) Renin-angiotensin system inhibition in advanced chronic kidney disease. N Engl J Med 387:2021–2032. https://doi.org/10.1056/NEJMoa2210639CrossRefPubMed

71.

Bowling CB, Sanders PW, Allman RM, Rogers WJ, Patel K, Aban IB, Rich MW, Pitt B, White M, Bakris GC et al (2013) Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial. Int J Cardiol 167:151–156. https://doi.org/10.1016/j.ijcard.2011.12.056CrossRefPubMed

72.

McCallum W, Tighiouart H, Ku E, Salem D, Sarnak MJ (2019) Acute declines in estimated glomerular filtration rate on enalapril and mortality and cardiovascular outcomes in patients with heart failure with reduced ejection fraction. Kidney Int 96:1185–1194. https://doi.org/10.1016/j.kint.2019.05.019CrossRefPubMedPubMedCentral

73.

Pitt B, Bushinsky DA, Kitzman DW, Ruschitzka F, Metra M, Filippatos G, Rossignol P, Du Mond C, Garza D, Berman L et al (2018) Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. ESC Heart Fail 5:257–266. https://doi.org/10.1002/ehf2.12265CrossRefPubMedPubMedCentral

74.

Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ, Investigators P-H (2011) Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 32:820–828. https://doi.org/10.1093/eurheartj/ehq502CrossRefPubMedPubMedCentral

75.

Ruilope LM, Tamargo J (2017) Renin-angiotensin system blockade: finerenone. Nephrol Ther 13(Suppl 1):S47–S53. https://doi.org/10.1016/j.nephro.2017.02.003CrossRefPubMed

76.

Craft J (2004) Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure. Proc (Bayl Univ Med Cent) 17:217–220. https://doi.org/10.1080/08998280.2004.11927973CrossRefPubMed

77.

Hauben M, Reich L, Gerrits CM, Madigan D (2007) Detection of spironolactone-associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES). Drug Saf 30:1143–1149. https://doi.org/10.2165/00002018-200730120-00006CrossRefPubMed

78.

Zannad F, McMurray JJ, Drexler H, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B (2010) Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail 12:617–622. https://doi.org/10.1093/eurjhf/hfq049CrossRefPubMed

79.

Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, Group EHS (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11–21. https://doi.org/10.1056/NEJMoa1009492

80.

McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K et al (2013) Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 15:1062–1073. https://doi.org/10.1093/eurjhf/hft052CrossRefPubMedPubMedCentral

81.

Desai AS, Vardeny O, Claggett B, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Zile MR, Lefkowitz M, Shi V et al (2017) Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiol 2:79–85. https://doi.org/10.1001/jamacardio.2016.4733CrossRefPubMed

82.

Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A, Bowman L, Brunskill N, Cockwell P, Hill M et al (2018) Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease. Circulation 138:1505–1514. https://doi.org/10.1161/CIRCULATIONAHA.118.034818CrossRefPubMed

83.

Abbott KC, Trespalacios FC, Agodoa LY, Taylor AJ, Bakris GL (2004) beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med 164:2465–2471. https://doi.org/10.1001/archinte.164.22.2465CrossRefPubMed

84.

Ghali JK, Wikstrand J, Van Veldhuisen DJ, Fagerberg B, Goldstein S, Hjalmarson A, Johansson P, Kjekshus J, Ohlsson L, Samuelsson O et al (2009) The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF). J Card Fail 15:310–318. https://doi.org/10.1016/j.cardfail.2008.11.003CrossRefPubMed

85.

Cice G, Ferrara L, D’Andrea A, D’Isa S, Di Benedetto A, Cittadini A, Russo PE, Golino P, Calabro R (2003) Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 41:1438–1444. https://doi.org/10.1016/s0735-1097(03)00241-9CrossRefPubMed

86.

Tieu A, Velenosi TJ, Kucey AS, Weir MA, Urquhart BL (2018) Beta-blocker dialyzability in maintenance hemodialysis patients: a randomized clinical trial. Clin J Am Soc Nephrol 13:604–611. https://doi.org/10.2215/CJN.07470717CrossRefPubMedPubMedCentral

87.

Voors AA, van Veldhuisen DJ, Robertson M, Ford I, Borer JS, Bohm M, Komajda M, Swedberg K, Tavazzi L, Investigators S (2014) The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. Eur J Heart Fail 16:426–434. https://doi.org/10.1002/ejhf.59

88.

Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383:1436–1446. https://doi.org/10.1056/NEJMoa2024816CrossRefPubMed

89.

Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:1413–1424. https://doi.org/10.1056/NEJMoa2022190CrossRefPubMed

90.

Sarafidis P, Ortiz A, Ferro CJ, Halimi JM, Kreutz R, Mallamaci F, Mancia G, Wanner C, Hypertension the Kidney' working group of the European Society of H et al (2021) Sodium--glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun. J Hypertens 39:1090–1097. https://doi.org/10.1097/HJH.0000000000002776

91.

The E-KCG, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ et al (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388:117–127. https://doi.org/10.1056/NEJMoa2204233CrossRef

92.

Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO et al (2011) Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 364:797–805. https://doi.org/10.1056/NEJMoa1005419CrossRefPubMedPubMedCentral

93.

Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, Tartaglia K, Chenot F, Moubayed S, Dierckx R et al (2022) Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med 387:1185–1195. https://doi.org/10.1056/NEJMoa2203094CrossRefPubMed

94.

Yamada T, Ueyama H, Chopra N, Yamaji T, Azushima K, Kobayashi R, Kinguchi S, Urate S, Suzuki T, Abe E et al (2020) Systematic review of the association between worsening renal function and mortality in patients with acute decompensated heart failure. Kidney Int Rep 5:1486–1494. https://doi.org/10.1016/j.ekir.2020.06.031CrossRefPubMedPubMedCentral

95.

Testani JM, Brisco MA, Turner JM, Spatz ES, Bellumkonda L, Parikh CR, Tang WH (2014) Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail 7:261–270. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000895CrossRefPubMed

96.

Voors AA, Davison BA, Teerlink JR, Felker GM, Cotter G, Filippatos G, Greenberg BH, Pang PS, Levin B, Hua TA et al (2014) Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome–an analysis from RELAX-AHF. Eur J Heart Fail 16:1230–1240. https://doi.org/10.1002/ejhf.170CrossRefPubMed

97.

Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL et al (2010) Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 363:2385–2395. https://doi.org/10.1056/NEJMoa1009540CrossRefPubMed

98.

Turakhia MP, Blankestijn PJ, Carrero JJ, Clase CM, Deo R, Herzog CA, Kasner SE, Passman RS, Pecoits-Filho R, Reinecke H et al (2018) Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur Heart J 39:2314–2325. https://doi.org/10.1093/eurheartj/ehy060CrossRefPubMedPubMedCentral

99.

Morton JB, Wong MCG (2019) Leadless pacing in hemodialysis patients. JACC Clin Electrophysiol 5:171–173. https://doi.org/10.1016/j.jacep.2019.01.006CrossRefPubMed

100.

Tompkins C, McLean R, Cheng A, Brinker JA, Marine JE, Nazarian S, Spragg DD, Sinha S, Halperin H, Tomaselli GF et al (2011) End-stage renal disease predicts complications in pacemaker and ICD implants. J Cardiovasc Electrophysiol 22:1099–1104. https://doi.org/10.1111/j.1540-8167.2011.02066.xCrossRefPubMed

101.

Tan CS, Jie C, Joe J, Irani ZD, Ganguli S, Kalva SP, Wicky S, Wu S (2013) The impact of transvenous cardiac devices on vascular access patency in hemodialysis patients. Semin Dial 26:728–732. https://doi.org/10.1111/sdi.12073CrossRefPubMed

102.

Koman E, Gupta A, Subzposh F, Saltzman H, Kutalek SP (2016) Outcomes of subcutaneous implantable cardioverter-defibrillator implantation in patients on hemodialysis. J Interv Card Electrophysiol 45:219–223. https://doi.org/10.1007/s10840-015-0093-2CrossRefPubMed

103.

El-Chami MF, Clementy N, Garweg C, Omar R, Duray GZ, Gornick CC, Leyva F, Sagi V, Piccini JP, Soejima K et al (2019) Leadless pacemaker implantation in hemodialysis patients: experience with the micra transcatheter pacemaker. JACC Clin Electrophysiol 5:162–170. https://doi.org/10.1016/j.jacep.2018.12.008CrossRefPubMed

104.

Timoteo AT, Mano TB (2023) Efficacy of peritoneal dialysis in patients with refractory congestive heart failure: a systematic review and meta-analysis. Heart Fail Rev. https://doi.org/10.1007/s10741-023-10297-3CrossRefPubMedPubMedCentral

105.

Koch M, Haastert B, Kohnle M, Rump LC, Kelm M, Trapp R, Aker S (2012) Peritoneal dialysis relieves clinical symptoms and is well tolerated in patients with refractory heart failure and chronic kidney disease. Eur J Heart Fail 14:530–539. https://doi.org/10.1093/eurjhf/hfs035CrossRefPubMed

106.

Wojtaszek E, Grzejszczak A, Niemczyk S, Malyszko J, Matuszkiewicz-Rowinska J (2019) Peritoneal Ultrafiltration in the long-term treatment of chronic heart failure refractory to pharmacological therapy. Front Physiol 10:310. https://doi.org/10.3389/fphys.2019.00310CrossRefPubMedPubMedCentral

107.

Cnossen TT, Kooman JP, Krepel HP, Konings CJ, Uszko-Lencer NH, Leunissen KM, van der Sande FM (2012) Prospective study on clinical effects of renal replacement therapy in treatment-resistant congestive heart failure. Nephrol Dial Transplant 27:2794–2799. https://doi.org/10.1093/ndt/gfr756CrossRefPubMed

108.

Nunez J, Gonzalez M, Minana G, Garcia-Ramon R, Sanchis J, Bodi V, Nunez E, Puchades MJ, Palau P, Merlos P et al (2012) Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure. Eur J Heart Fail 14:540–548. https://doi.org/10.1093/eurjhf/hfs013CrossRefPubMed

109.

Kazory A, Bargman JM (2019) Defining the role of peritoneal dialysis in management of congestive heart failure. Expert Rev Cardiovasc Ther 17:533–543. https://doi.org/10.1080/14779072.2019.1637254CrossRefPubMed

110.

Kunin M, Carmon V, Arad M, Levin-Iaina N, Freimark D, Holtzman EJ, Dinour D (2015) Inflammatory Biomarkers in refractory congestive heart failure patients treated with peritoneal dialysis. Biomed Res Int 2015:590851. https://doi.org/10.1155/2015/590851

111.

Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WHW (2009) Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 53:589–596. https://doi.org/10.1016/j.jacc.2008.05.068CrossRefPubMedPubMedCentral

112.

Iadarola GM, Lusardi P, La Milia V, Amici G, Santarelli S, Virga G, Basile C, Bertoli S, Bonofiglio R, Del Rosso G et al (2013) Peritoneal ultrafiltration in patients with advanced decompensated heart failure. J Nephrol 26(Suppl 21):159–176. https://doi.org/10.5301/JN.2013.11639CrossRefPubMed

113.

El-Reshaid W, Al-Disawy H, Nassef H, Alhelaly U (2016) Comparison of peritonitis rates and patient survival in automated and continuous ambulatory peritoneal dialysis: a 10-year single center experience. Ren Fail 38:1187–1192. https://doi.org/10.1080/0886022X.2016.1209025CrossRefPubMed

114.

Perl J, Fuller DS, Bieber BA, Boudville N, Kanjanabuch T, Ito Y, Nessim SJ, Piraino BM, Pisoni RL, Robinson BM et al (2020) Peritoneal dialysis-related infection rates and outcomes: results from the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). Am J Kidney Dis 76:42–53. https://doi.org/10.1053/j.ajkd.2019.09.016CrossRefPubMed

115.

Nessim SJ, Bargman JM, Austin PC, Nisenbaum R, Jassal SV (2009) Predictors of peritonitis in patients on peritoneal dialysis: results of a large, prospective Canadian database. Clin J Am Soc Nephrol 4:1195–1200. https://doi.org/10.2215/CJN.00910209CrossRefPubMedPubMedCentral

116.

Morales RO, Barbosa F, Farre N (2021) Peritoneal dialysis in heart failure: focus on kidney and ventricular dysfunction. Rev Cardiovasc Med 22:649–657. https://doi.org/10.31083/j.rcm2203075

117.

Amici G, Bergia R, Cancarini G, Corciulo R, Feriani M, Iadarola GM, La Milia V, Manili L, Neri L, Russo R et al (2013) Prescription in peritoneal dialysis. J Nephrol 26(Suppl 21):83–95. https://doi.org/10.5301/JN.2013.11635CrossRefPubMed

118.

Popovich RP, Moncrief JW, Nolph KD, Ghods AJ, Twardowski ZJ, Pyle WK (1978) Continuous ambulatory peritoneal dialysis. Ann Intern Med 88:449–456. https://doi.org/10.7326/0003-4819-88-4-449CrossRefPubMed

119.

Frampton JE, Plosker GL (2003) Icodextrin: a review of its use in peritoneal dialysis. Drugs 63:2079–2105. https://doi.org/10.2165/00003495-200363190-00011CrossRefPubMed

120.

Mistry CD, Gokal R, Peers E (1994) A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter investigation of icodextrin in ambulatory peritoneal dialysis. Kidney Int 46:496–503. https://doi.org/10.1038/ki.1994.300

121.

Grossekettler L, Schmack B, Meyer K, Brockmann C, Wanninger R, Kreusser MM, Frankenstein L, Kihm LP, Zeier M, Katus HA et al (2019) Peritoneal dialysis as therapeutic option in heart failure patients. ESC Heart Fail 6:271–279. https://doi.org/10.1002/ehf2.12411CrossRefPubMedPubMedCentral

122.

Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, Missov ED, Clerico A, Tognoni G, Cohn JN et al (2006) Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 52:1528–1538. https://doi.org/10.1373/clinchem.2006.069575CrossRefPubMed

123.

McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE, Herrmann HC, Steg PG, Westheim A, Knudsen CW et al (2003) B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 41:571–579. https://doi.org/10.1053/ajkd.2003.50118CrossRefPubMed

124.

Damman K, Ng Kam Chuen MJ, MacFadyen RJ, Lip GY, Gaze D, Collinson PO, Hillege HL, van Oeveren W, Voors AA, van Veldhuisen DJ (2011) Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. J Am Coll Cardiol 57:2233–2241. https://doi.org/10.1016/j.jacc.2010.10.065

125.

CTS Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:1429–1435. https://doi.org/10.1056/NEJM198706043162301

126.

Cohn JN, Tognoni G (2001) Valsartan heart failure trial, I. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667–1675. https://doi.org/10.1056/NEJMoa010713

127.

Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709–717. https://doi.org/10.1056/NEJM199909023411001

128.

(1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353:9–13

129.

Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G et al (2020) Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 382:1883–1893. https://doi.org/10.1056/NEJMoa1915928CrossRefPubMed

130.

Mavrakanas TA, Soomro QH, Charytan DM (2022) Hydralazine-Isosorbide Dinitrate Use in Patients With End-Stage Kidney Disease on Dialysis. Kidney Int Rep 7:1332–1340. https://doi.org/10.1016/j.ekir.2022.03.032CrossRefPubMedPubMedCentral

131.

Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K et al (2015) Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131:54–61. https://doi.org/10.1161/CIRCULATIONAHA.114.013748CrossRefPubMed

132.

McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995–2008. https://doi.org/10.1056/NEJMoa1911303CrossRefPubMed

Title: Assessment and management of heart failure in patients with chronic kidney disease
Authors: Andrea Igoren Guaricci
Francesca Sturdà
Roberto Russo
Paolo Basile
Andrea Baggiano
Saima Mushtaq
Laura Fusini
Fabio Fazzari
Fulvio Bertandino
Francesco Monitillo
Maria Cristina Carella
Marco Simonini
Gianluca Pontone
Marco Matteo Ciccone
Giuseppe Grandaliano
Giuseppe Vezzoli
Francesco Pesce
Publication date: 20-09-2023
Publisher: Springer US
Keywords: Heart Failure
Chronic Kidney Disease
Peritoneal Dialysis
Biomarkers
Published in: Heart Failure Reviews / Issue 2/2024
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-023-10346-x

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Assessment and management of heart failure in patients with chronic kidney disease

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2024

The sympathetic nervous system in heart failure revisited

Anti-bradycardia pacing—impact on patients with HFpEF: a systematic review

Can the hemodynamic model in heart failure be restored based on analysis of ventricular-arterial coupling?

Correction to: Clinical staging of Anderson‑Fabry cardiomyopathy: an operative proposal

Clinical staging of Anderson-Fabry cardiomyopathy: An operative proposal

Advance in the pharmacological and comorbidities management of heart failure with preserved ejection fraction: evidence from clinical trials

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page